CLOSE
Tags Posts tagged with "medRxiv"

medRxiv

by -
0 745
Dr. John Inglis Photo from CSHL

By Daniel Dunaief

Evolution doesn’t just favor species that have adaptive advantages in a changing environment. It’s also relevant for businesses, as they move into new markets, and even to scientific publishing.

A preprint scientific publishing effort that started in 2013 at Cold Spring Harbor Laboratory with bioRxiv and expanded in 2019 with medRxiv is making changes that its creators believe positions it to grow while continuing to serve the scientific community.

BioRxiv and medRxiv are becoming an independent nonprofit, called openRxiv. The new format, which takes the preprint offerings outside the home of Cold Spring Harbor Laboratory, will create a product that is outside the realm of a single institution and that has transparent governance.

“We had an independent needs assessment done by a consulting company,” said Dr. John Inglis, Chair of the openRxiv Scientific and Medical Advisory Board. The governance needed to be “more community-oriented, with not just funders, but committees of working scientists.”

The Chan Zuckerberg Initiative, which has been the major funder for the preprint services, understood the benefits of transitioning to an independent non profit. They also wanted to “see a diversification of funding” from other sources and contributors, Inglis said.

Up until co-founders Inglis and Dr. Richard Sever, Chief Science and Strategy Officer at openRxiv created these two preprint services, most biological and medical scientific discoveries progressed through the slower pace of peer review publishing that helps them advance their fields while sharing their results.

Preprints, however, greatly accelerated that process by allowing researchers to display their work before peer review. While scientists might need to amend their findings by adding further studies, these preprints enable researchers to do the equivalent of presenting their research to a worldwide audience, the way scientists do at meetings.

The preprint servers are “like the biggest conference you’ve ever seen, with millions of people,” said Inglis.

A growing market 

In each month of the last quarter of 2024, bioRxiv recorded between 8 million and 9.7 million page views, with between 4.7 million and 6.8 million downloads, Inglis said. MedRxiv, meanwhile, had between 1.8 million and 1.9 million page views with a million downloads per month.

With more than 110 new articles per day last year, bioRxiv added 11 percent more original preprints last year. MedRxiv grew by 12 percent, adding 12,863 preprints last year, or about 35 new articles per day.

MedRxiv launched the year before the pandemic and quickly became the major channel of communication for pandemic-related preprints.

In 2020, when pandemic related coverage accounted for 80 percent of everything posted, medRxiv shared a total of 14,070 research pieces.

At this point, contributing authors have come from 190 countries. The most prolific contributors are the United States and the United Kingdom. With readers coming from around the world, openRxiv’s primary task is to convert some of the readers from other countries into contributors, Inglis said.

Search for a CEO

OpenRxiv creates opportunities for several executives.

Sever, who had been CSHL Press Assistant Director, will leave the lab to become the chief scientific and strategy officer for openRxiv.

At the same time, openRxiv, which has an annual budget of $3 million, has hired a recruiting firm to lead the search for its first Chief Executive Officer.

The new CEO will need to “believe in the mission, promise, potential and ambition of openRxiv,” said Inglis, as the CEO will be the “principal ambassador” for the effort.

The new leader will also need experience running a complex organization with various stakeholders and that has community engagement.

Inglis described the current employees, which includes eight full time staff, as “fantastically motivated.” He anticipates the new leader could be announced as soon as three or four months from now.

Expanded opportunities

The preprint servers has appealed to academic institutions directly for ongoing repeated support, through a membership model.

Indeed, preprint managers reached out on the 10th anniversary of bioRxiv and received backing from institutions that are listed on every bioRxiv and medRxiv preprint.

“We want to build on that, to reach out to more institutions,” said Inglis. He wants to have a “real dialog with them about what these servers mean to their faculty and how we can be useful in terms of their operations.”

Some academic institutions don’t always know which research studies are appearing on these servers.

OpenRxiv can give universities information for researchers who are posting their studies.

Additionally, these servers have been offering authors the chance to transfer their manuscripts to particular journals. At this point, openRxiv has connections with 45 publishers who oversee 380 journals.

Inglis said they charge a small fee to set that up and described this effort as the “germ” of a business model. He anticipates that openRxiv could provide more of these connections.

Professional pathways

Authors have the ability to correct or amend their work on these servers. The preprints encourage people to explain the changes, while discouraging too many corrections or changes for grammatical reasons. The record for revisions on bioRxiv or medRxiv is seven.

Inglis has heard from numerous researchers who are grateful to increase the visibility of their work and their careers in a timely way.

These non peer reviewed studies can help scientists move up the ladder, getting job offers from other institutions while they await publication in a journal.

Ongoing support

CSHL, BMJ Group and Yale School of Medicine remain key supporters of openRxiv.

“OpenRxiv is the natural evolution and progression of free and open access to scientific information,” Bruce Stillman, President and CEO of CSHL said in a statement. “BioRxiv and medRxiv have revolutionized the field of science and scientific publishing. The establishment of openRxiv will allow for continued innovation in how the latest scientific results are communicated.”

In the last few weeks, openRxiv had the first in a series of webinars they are mounting on their own behalf. They plan to offer them to institutions across the world and believe they are an effective way to engage with the world of international science.

OpenRxiv is in conversation with faculty at an institution in Japan about organizing a webinar and will reach out to institutions in India. Staff at openRxiv plan to expand the scope of this process by contacting authors in potential locations who have multiple articles on the servers.

The response from students is an “encouragement to do more,” said Inglis. “Having more people and more resources will allow us to ramp up educational development of what we’re doing.”

by -
0 1390
John Inglis. Photo courtesy of CSHL

By Daniel Dunaief

In the post COVID-19 world, the pace of science and, in particular, scientific publishing has changed, giving researchers a sense of urgency to share information that might lead to preventions, treatments and cures.

Cold Spring Harbor Laboratory has produced two preprint research services, bioRxiv and MedRxiv, that complement the longer peer-reviewed path to publication.

After numerous scientists restructured their labs to contribute to the growing body of knowledge and information about COVID-19, these researchers turned to preprint services to share the results of their work and the evolution of their thoughts on how to defeat the virus.

“It’s absolutely unprecedented for scientists to drop what they are doing and switch their focus to something completely new to aid society and mankind in general,” said John Inglis, the co-founder of bioRxiv and one of the members of joint management group for medRxiv.

MedRxiv, which started in June of 2019, helped provide the scientific community with an outlet for their health science research, with the caveat that the results haven’t received a thorough peer review, as they might in the New England Journal of Medicine, Cell, or other periodicals.

The number of preprint research papers has climbed dramatically this year, as scientists race to get their results from the bench to the server. The number of papers in bioRxiv increased to 88,268 in June from 71,458 in January. The increase at the newer medRxiv is much more dramatic, climbing from 953 in January to 7,541 in June.

The number of pandemic related papers on medRxiv and bioRxiv in total is 6,458, with 5,133 on medRxiv and 1,325 on bioRxiv.

Pandemic-related papers account for close to 70 percent of the new research published on medRxiv since January 1st, while the percentage of virus-related papers on bioRxiv is 6.2%, in large part because bioRxiv includes numerous other subject areas, including ecology, bioinformatics, plant biology and zoology.

The world has taken notice of all these papers, with page views peaking in April for medRxiv to almost 11 million for the month.

While the papers aren’t peer reviewed, the managers of these sites urge readers to remain cautious in their interpretation and use of these findings, while the scientific community continues to duplicate any encouraging or compelling results.

“We remind people all the time that these are preprints,” Inglis said, as the site has numerous reminders about the early nature of the findings. “They are preliminary reports and should not guide clinical practice or be reported as established information. That’s a battle we’re still fighting.”

The peer review process has also picked up some speed, as journals, inundated with potential game-changing material, have been accelerating the process of reading and reviewing papers. The median time between posting an article on bioRxiv and publication in a journal before the pandemic was nine months. Some papers in medRxiv have been published in journal in as few as 35 days.

For medRxiv, the screening process requires an ethics statement, a funding statement, and any potential conflicts of interest. These requirements are “all far more familiar in medical publishing than in scientific publishing,” said Inglis.

At bioRxiv, which recently introduced a competing interest statement as well for authors, freelancers and a group of Principal Investigators look at everything before it posts, to make sure it’s science and that it’s not dangerous. The screeners turn the manuscripts back to the team if they have any concerns.

“We felt, early in the pandemic, that it was necessary to make sure we have people with expertise in outbreak science,” Inglis explained. “We brought on volunteers.”

According to Inglis, the percentage of manuscripts that scientists submit, but that bioRxiv doesn’t publish, is between 5 and 10 percent, while that figure is closer to 20 to 25 percent for medRxiv.

Inglis said numerous scientists have done some modeling based on public data, but that the preprints don’t accept those papers unless they contain additional research.

The preprint management team was “worried about the indiscriminate use of these models to guide public policy,” he said.

Additionally, the team excluded manuscripts that might be dangerous to human health or human-health related behavior. They didn’t want people to rush out and take something that, theoretically, might help, but that hasn’t received sufficient testing. A treatment might block a receptor, but also have significant side effects.

Inglis said the team of people who work at the preprints, which includes five full-time preprint-platform dedicated staff members and seven other CSHL staff with other responsibilities, including the founders, tech developers and production staff, worked seven days a week, with long working days to meet the increased need and demand.

People working on this effort “are not doing it because they are getting rich or handsomely acknowledged.” An arduous job with thousands of papers, the staff are working out of a “sense of purpose and mission,” Inglis explained.

The Chan Zuckerberg Initiative and CSHL provide financial support for these preprints. The research community has shared their appreciation for these preprints and CSHL generously acknowledges the work of the staff.

Inglis and Richard Sever co-founded bioRxiv. MedRxiv is managed by Sever and Inglis in collaboration with Professors Harlan Krumholz and Joe Ross from Yale and Dr. Theo Bloom and Claire Rawlinson from BMJ, which was originally called the British Medical Journal.

Inglis said numerous papers have become game-changers in the battle against the virus, including a study from two weeks ago in the United Kingdom on dexamethasone, a steroid that was proven effective in severe cases of COVID-19. Indeed, just recently, a Bethesda hospital became the first in the nation to use the steroid to combat the virus.

The team working in preprints at CSHL appreciates the opportunity to contribute to the public health crisis.

Inglis is pleased with how the community trusted the preprints with their work, while numerous members of the community helped screen manuscripts and provide advice about how to react to the needs of the pandemic.

TBR News Media is your local news and entertainment website.
We provide you with the latest breaking news and information for your community.
Contact us: [email protected]

Most Viewed

©